Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SinoMab Bioscience Ltd. ( (HK:3681) ) has issued an announcement.
SinoMab BioScience Limited has called its 2026 annual general meeting for 12 June 2026 in Hong Kong, where shareholders will review the 2025 audited financial statements and reports, vote on the re-election of several directors, and approve directors’ remuneration. The agenda also includes the election of a new non-executive director, renewal of Ernst & Young as auditor, and the granting of general mandates for the board to repurchase up to 10% of the company’s shares and to issue additional shares or dispose of treasury stock, reinforcing governance continuity and capital management flexibility for the company and its investors.
These resolutions, if approved, will maintain board stability while adding new expertise, and confirm the company’s existing audit relationship with Ernst & Young. The proposed share repurchase and issuance mandates are standard for Hong Kong-listed firms and would provide SinoMab with tools to manage its capital structure, support potential fundraising, and respond to market conditions without seeking separate shareholder approvals for each transaction.
More about SinoMab Bioscience Ltd.
SinoMab BioScience Limited is a Hong Kong-incorporated biopharmaceutical company listed on the Hong Kong Stock Exchange. It focuses on the discovery, development and commercialization of antibody-based therapies, targeting autoimmune and other immunological diseases in domestic and international markets.
Average Trading Volume: 4,892,224
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.04B
For a thorough assessment of 3681 stock, go to TipRanks’ Stock Analysis page.